The oral delivery of small-molecule drugs with poor aqueous solubility represents an ongoing drug development challenge. Amorphous solid dispersions (ASDs) and lipid-based formulations (LBFs) have emerged as effective approaches to address this. This Perspective provides an overview of the design of ASDs and LBFs and examines the mechanisms underlying their enhanced bioavailability. Preclinical, clinical and commercialization considerations, as well as next-generation oral formulations, are discussed.
- Keisuke Ueda
- Christopher J. H. Porter
- Lynne S. Taylor